Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

NCT00364351 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1574

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Vandetanib
DRUG: Erlotinib

Sponsor

Genzyme, a Sanofi Company